Assessment of Patients Adherence to Oral Regimen of Drug-Resistant Tuberculosis among Iraqi Patients
DOI:
https://doi.org/10.32947/ajps.v25i1.1109Keywords:
adherence, non-adherence, oral regimen for drug-resistant TB treatmentAbstract
Background: Drug-resistant tuberculosis is an airborne chronic infectious disease that has evolved resistance to at least two anti-TB medications (isoniazid and rifampin). For the drug-resistant tuberculosis epidemic to be controlled, it is essential that patients be cured. However, therapeutic failure is often caused by patients who don't adhere to their prescribed regimen.
Incomplete treatment facilitates the spread of multidrug-resistant tuberculosis and the subsequent emergence of severely drug-resistant TB. It is crucial to determine the prevalence of pharmacological non-adherence among these patients and to know the reasons for this non-adherence.
Result: The study involved a total of 67 drug-resistant tuberculosis patients, and the duration of their treatment was 14 weeks, mostly males, with a majority being urban residents. within the first two weeks, only 1 patient interrupted the treatment course for a short term. At six weeks (6%) of patients interrupted the course, within the ten weeks, there was no interruption and 100% of adhere to treatment was observed. At fourteen weeks, (14.9%) of the patients interrupted the course. The patients who interrupted to treatment were mostly due to far residence because the TB institute was the only institute in Iraq where patients treated and diagnosed in Baghdad, others of them were causeless interrupted their treatment, and fewer due to adverse drug events such as anemia due to took linezolid drug and arthralgia because of levofloxacin drug. There was not a statistically significant difference between those who adhered to the correct dose (the correct count number of pills) and those who adhered to a low dose (low count number of pills) with demographic data.
Conclusion: Patient interrupting the treatment course was noticed mostly in the six and fourteen weeks, patient characteristics did not impact their adherence to the proper dose.
References
1- Kadhim AA, AL-Marjan MF, Kadhim KA, Manki AA. Isolation of Mycobacterium tuberculosis and testing their susceptibility to antimicrobial agents by using Bactec 960. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2013 Jun 1;13(1):175–181.
2- Nguyen TMP, Nguyen BH, Hoang TTT, Nguyen HA, Vu DH, Nguyen MH, et al. Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam. Front Pharmacology. 2022;4292.
3- Al-Badri HB, Al-Ani WMK, Mutalib A, Naser AG. Detection of Nicotine in Equisetum arvense Grown Naturally in Iraq. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2016 Dec 1;16(2):40–44.
4- David A, de Vos M, Scott L, da Silva P, Trollip A, Ruhwald M, et al. Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization–Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and Isoniazid. Journal of Molecular Diagnostics. 2023;25(1):46–56.
5- WHO consolidated guidelines on drug-resistant tuberculosis treatment. (WHO), editor. Geneva: World Health Organization; 2019. P 9–10.
6- WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. 2022nd ed. editor. Geneva: World Health Organization; 2022. P16- 17.
7- Wang Y, Chen H, Huang Z, McNeil EB, Lu X, Chongsuvivatwong V. Drug non-adherence and reasons among multidrug-resistant tuberculosis patients in Guizhou, China: Patient Prefer Adherence. 2019;1641–1653.
8- Podewils LJ, Gler MTS, Quelapio MI, Chen MP. Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes. PLoS One. 2013 Jul 29;8(7).
9- World Health Organization. Global Tuberculosis Report, 2018. Geneva: WHO/CDS/TB/2018.20. Geneva, Switzerland.
10- Bastard M, Sanchez-Padilla E, Hewison C, Hayrapetyan A, Khurkhumal S, Varaine F, et al. Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. J Infect Dis. 2015 May 15;211(10):1607–1615.
11- Schaefer MR, Wagoner ST, Young ME, Rawlinson AR, Kavookjian J, Shapiro SK, et al. Subjective versus objective measures of medication adherence in adolescents/young adults with attention-deficit hyperactivity disorder. Journal of Developmental & Behavioral Pediatrics. 2019;40(1):54–59.
12- Mulu Fentie A, Tadesse F, Engidawork E, Gebremedhin A. Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopians with chronic myeloid leukemia. PLoS One. 2019 ;14(3) : e0213557.
13- Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clinical Infectious Diseases. 2023;76(3):e938–e946.
14- Massud A, Syed Sulaiman SA, Ahmad N, Shafqat M, Chiau Ming L, Khan AH. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study. Front Pharmacology. 2022 Jun 2;13.
15- Singh M, Malik A, Devhare D, et al. View of Comparative Case Study On Tuberculosis Patients Between Rural And Urban Areas. Journal of Survey in Fisheries Sciences. 2023, 622-632.
16- Azzahrain AS, Afifah AN, Yamani LN. Detection of Tuberculosis in Toddlers and its Risk Factor at East Perak Health Center Surabaya. JURNAL KESEHATAN LINGKUNGAN. 2023 Apr 29;15(2):92–98.
17- Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.
18- Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine. 2022 Dec 22;387(25):2331–2343.
19- Carreras-Abad C, Espiau M, López-Seguer L, Martín-Begué N, Martín-Nalda A, Melendo-Pérez S, et al. Adverse Events Associated With New Injectable-Free Multidrug-Resistant Tuberculosis Drug Regimens. Arch Bronconeumolgy. 2020;56(12):823–825.
20- Huynh J, Marais BJ. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs. Ther Adv Infect Dis. 2019; 6:2049936119864737.
21- Wei XL, Yin J, Zou GY, Zhang ZT, Walley J, Harwell J, et al. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. International Journal of Tuberculosis and Lung Disease. 2015 Apr 1;19(4):413–419.
22- World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva: WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO; 2014.
23- Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis. 2010;14(3):275–281.
24- Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis. Am J Ther. 2016 Mar 1;23(2):e521–e530.
25- Wang Y, Wang X, Xu J, et al. Treatment for MDR-TB. National Handbook for MDR-TB Control and Management, 2012. Li X. Beijing, China: Military Medical Science Press; 2012:16–18.
26- Yang YB, Xu L. Analysis of influencing factors on non-enrolment treatment of MDR-TB cases in Yunnan province. The 10th International Conference on Public Health Among Greater Mekong Sub-region Countries –Health Equity and Response to Crisis. November; 2018; Kumming, China.
27- Hutchison C, Khan MS, Yoong J, Lin X, Coker RJ. Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China. BMC Public Health. 2017 Feb 22;17(1):1–11.
28- Yin J, Wang XM, Zhou L, Wei XL. The relationship between social support, treatment interruption and treatment outcome in patients with multidrug-resistant tuberculosis in China: a mixed-methods study. Trop Med Int Health. 2018;23(6):668–677.
29- Martelli G, Antonucci R, Mukurasi A, Zepherine H, Nöstlinger C. Adherence to antiretroviral treatment among children and adolescents in Tanzania: Comparison between pill count and viral load outcomes in a rural context of Mwanza region. PLoS One. 2019 Mar 1;14(3).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Noor Alaa Jasim, Manal Khalid Abdulridha, Ahmed Asmar Mankhy, Ahmed Hadi Tarish
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
